Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s13568-025-01837-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.
Ophthalmol Ther
March 2025
Team "Staphylococcal Pathogenesis", CIRI - Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France.
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of sight-threatening infections in the US. These strains pose a significant challenge in managing ocular infections, as they frequently exhibit resistance to first-line empirical antibiotics. To assess the potential of bacteriophages as innovative topical therapies for treatment of recalcitrant ocular infections, we evaluated the in vitro antimicrobial activity of a set of anti-S.
View Article and Find Full Text PDFRecent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.
AMB Express
March 2025
Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A.
View Article and Find Full Text PDFDifferences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages.
Eur J Immunol
March 2025
Blacktown Clinical School, Western Sydney University, Sydney, NSW, Australia.
Bacteriophages (phages) are emerging as a viable adjunct to antibiotics for the treatment of multidrug-resistant (MDR) bacterial infections. While intravenous phage therapy has proven successful in many cases, clinical outcomes remain uncertain due to a limited understanding of host response to phages. In this study, we conducted a comprehensive examination of the interaction between clinical-grade phages used to treat MDR Escherichia coli and Klebsiella pneumoniae infections, and human peripheral blood immune cells.
View Article and Find Full Text PDFBiological function identification of phage holin Hol-4086 and treatment of infection.
Front Microbiol
February 2025
Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
The treatment of infections caused by drug-resistant has become increasingly difficult. In this study, the complete genome of phage 4086-1 against was sequenced and shown to be 17,960 bp in size, with a GC content of 29.14%.
View Article and Find Full Text PDFThe landscape of biofilm models for phage therapy: mimicking biofilms in diabetic foot ulcers using 3D models.
Front Microbiol
February 2025
Goethe University Frankfurt, University Hospital Frankfurt, Department II of Internal Medicine, Infectious Diseases, Frankfurt, Germany.
Diabetic foot ulcers (DFU) affect up to 15-25% of patients suffering from diabetes and are considered a global health concern. These ulcers may result in delayed wound healing and chronic infections, with the potential to lead to amputations. It has been estimated that 85% of diabetes-related amputations are preceded by a diagnosis of DFU.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!